临床试验证明重组链激酶为一安全、有效的新型溶栓药。
The clinical studies demonstrated that r-SK is a safe and effective new type thrombolytic agent.
由于现用溶栓药或多或少都有一些缺陷，因此人们一直都在研制开发新型的溶血栓药物。
Because most of the using thrombolytics have defect, it is necessary to develop new thrombolytics.
文章对新型溶血栓药物及溶栓辅助药的研制进展和临床应用现状进行了综述。
Here reviewed were recent progress in research and current events of clinical application of recombinant thrombolytic agents and thrombolytic adjuvant.
从脑片染色结果及给药后不同时间点大鼠血液中纤溶酶原激活剂和其抑制剂的含量变化显示用该工艺纯化的蚓激酶有较好的溶栓作用。
The EFE purified through the process mentioned above has high specific activity and good effect in treating cerebral ischemia. Concerntration oft-PA and PAI, in respect of the rats in…
从脑片染色结果及给药后不同时间点大鼠血液中纤溶酶原激活剂和其抑制剂的含量变化显示用该工艺纯化的蚓激酶有较好的溶栓作用。
The EFE purified through the process mentioned above has high specific activity and good effect in treating cerebral ischemia. Concerntration oft-PA and PAI, in respect of the rats in…
应用推荐